Recursion climbs as experimental drug reduces polyp growth in rare disease trial

Shares of drug developer Recursion Pharma RXRX.O rise 6.2% to $5.05 premarket

Co says its experimental oral drug, REC-4881, helped reduce abnormal growths, called polyps, in the colon of patients with a rare genetic condition called familial adenomatous polyposis

In an early to mid-stage trial, 9 out of 11 patients maintained a durable reduction in total polyp burden, 12 weeks after discontinuing therapy

Co is looking to expand the study to a broader population of patients aged 18 years and above

Up to last close, stock down 30.3% YTD